Zevra beefs up rare dis­ease port­fo­lio via $91M ac­qui­si­tion of Ac­er Ther­a­peu­tics

Zevra Ther­a­peu­tics is set to buy Ac­er Ther­a­peu­tics in a deal worth up to $91 mil­lion, which finds the Flori­da-head­quar­tered biotech with an ad­di­tion­al two as­sets.

As a part of the deal, Zevra will ab­sorb Ac­er’s urea cy­cle dis­or­der treat­ment Ol­pru­va (sodi­um phenyl­bu­tyrate), which se­cured an FDA ap­proval in De­cem­ber last year, as well as be­ta-block­er celipro­lol, which is in a Phase III vas­cu­lar Ehlers-Dan­los syn­drome tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER